Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Impact of anti-androgen therapies on COVID-19 susceptibility: a case-control study in male population from two COVID-19 regional centers of Lombardy (Italy)

View ORCID ProfileMassimo Lazzeri, View ORCID ProfileStefano Duga, Elena Azzolini, View ORCID ProfileVittorio Fasulo, Nicolò Buffi, View ORCID ProfileAlberto Saita, The Humanitas COVID-19 Task Force, The Humanitas Gavazzeni COVID-19 Task Force, View ORCID ProfileRodolfo Hurle, Alessandro Nobili, Maurizio Cecconi, Paolo Casale, View ORCID ProfileRosanna Asselta
doi: https://doi.org/10.1101/2020.04.20.20068056
Massimo Lazzeri
1Humanitas Clinical and Research Center – IRCCS –, via Manzoni 56, 20089 Rozzano (Mi) – Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Massimo Lazzeri
  • For correspondence: massimo.lazzeri@humanitas.it stefano.duga@hunimed.eu
Stefano Duga
1Humanitas Clinical and Research Center – IRCCS –, via Manzoni 56, 20089 Rozzano (Mi) – Italy
2Humanitas University, Department of Biomedical Sciences, Via Rita Levi Montalcini 4, 20090 Pieve Emanuele – Milan, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Stefano Duga
  • For correspondence: massimo.lazzeri@humanitas.it stefano.duga@hunimed.eu
Elena Azzolini
1Humanitas Clinical and Research Center – IRCCS –, via Manzoni 56, 20089 Rozzano (Mi) – Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vittorio Fasulo
1Humanitas Clinical and Research Center – IRCCS –, via Manzoni 56, 20089 Rozzano (Mi) – Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Vittorio Fasulo
Nicolò Buffi
1Humanitas Clinical and Research Center – IRCCS –, via Manzoni 56, 20089 Rozzano (Mi) – Italy
2Humanitas University, Department of Biomedical Sciences, Via Rita Levi Montalcini 4, 20090 Pieve Emanuele – Milan, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alberto Saita
1Humanitas Clinical and Research Center – IRCCS –, via Manzoni 56, 20089 Rozzano (Mi) – Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Alberto Saita
1Humanitas Clinical and Research Center – IRCCS –, via Manzoni 56, 20089 Rozzano (Mi) – Italy
3Humanitas Gavazzeni-Castelli, Bergamo, Italy
Rodolfo Hurle
1Humanitas Clinical and Research Center – IRCCS –, via Manzoni 56, 20089 Rozzano (Mi) – Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Rodolfo Hurle
Alessandro Nobili
4Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Via Mario Negri, 2, 20156, Milan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maurizio Cecconi
1Humanitas Clinical and Research Center – IRCCS –, via Manzoni 56, 20089 Rozzano (Mi) – Italy
2Humanitas University, Department of Biomedical Sciences, Via Rita Levi Montalcini 4, 20090 Pieve Emanuele – Milan, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paolo Casale
1Humanitas Clinical and Research Center – IRCCS –, via Manzoni 56, 20089 Rozzano (Mi) – Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rosanna Asselta
1Humanitas Clinical and Research Center – IRCCS –, via Manzoni 56, 20089 Rozzano (Mi) – Italy
2Humanitas University, Department of Biomedical Sciences, Via Rita Levi Montalcini 4, 20090 Pieve Emanuele – Milan, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Rosanna Asselta
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Importance There are gender differences in vulnerability to the Coronavirus disease 2019 (COVID-19), with men experiencing more severe disease at any age. The use of anti-androgen drugs, like 5-alpha reductase inhibitors (5ARIs), could protect from severe pulmonary disease.

Objective To determine whether men who received 5ARIs for benign prostatic hyperplasia (BPH) have a lower risk of hospitalization for COVID-19.

Design This is a case-control study on patients hospitalized for COVID-19 (cases), matched to beneficiaries of the Lombardy Regional Health Service (controls).

Setting Data were collected by two high-volume COVID-19 regional centres of Lombardy (Italy) from 1st March to 24th April 2020.

Participants Consecutive patients positive for SARS-CoV-2 virus according to the WHO guidance, who required hospitalization.

Exposure BPH treatment with 5ARIs (finasteride/dutasteride) in the last six months.

Main Outcome(s) and Measure(s) The primary outcome was to compare the prevalence of male patients chronically exposed to 5ARIs, who required hospitalization for COVID-19, with the one of age-matched males in Lombardy.

Results Overall, 1,432 COVID-19 patients were included. Among the 943 males, 45 (4.77%) patients were exposed to chronic 5ARI therapy. COVID-19 patients aged >55 years under 5ARI treatment were significantly less than expected on the basis of the prevalence of 5ARI treatment among age-matched controls (5.57 vs. 8.14%; p=0.0083, 95%CI=0.75-3.97%). This disproportion was even higher for men aged >65 (7.14 vs. 12.31%; p=0.0001, 95%CI=2.83-6.97%).

Eighteen 5ARIs-patients died; the mean age of men who died was higher than those who did not: 75.98±9.29 vs. 64.78±13.57 (p<0.001). Cox regression and multivariable models did not show any correlation between the exposure to 5ARIs and protection against ICU admission or death: HR=0.79 (95%CI=0.54-1.15; p=0.22) and OR=1.23 (95%CI=0.81-1.87; p=0.33), respectively.

Conclusions and Relevance In this case-control study the use of 5ARIs was less frequent among patients hospitalized for COVID-19 than among controls, suggesting that men exposed to 5ARIs might be less vulnerable to severe COVID-19. This observation further supports the idea to test in randomized clinical trials whether anti-androgen therapies can prevent the transition from paucisymptomatic SARS-CoV-2 infection to overt pulmonary disease.

Question May treatment of benign prostatic hyperplasia with 5-alpha reductase inhibitors (5ARIs) impact on COVID-19-related hospitalization risk?

Findings In this case-control study, which compared 943 adult males hospitalized for COVID-19 with age-matched men from Lombardy (all beneficiaries of the Regional Health Service), the proportion of patients aged >55 years, who were exposed to 5ARIs (dutasteride, finasteride), was significantly lower (5.57%) than that of the general male population (8.14%) (p=0.0083, 95%CI=0.75-3.97%).

Meaning The use of 5ARIs was associated with a potential reduced risk of hospitalization for COVID-19 in men older than >55 years. This suggests the opportunity to test whether anti-androgen therapies can prevent the transition from paucisymptomatic SARS-CoV-2 infection to overt pulmonary disease.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

-

Author Declarations

All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.

Yes

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

not applicable

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted September 21, 2020.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Impact of anti-androgen therapies on COVID-19 susceptibility: a case-control study in male population from two COVID-19 regional centers of Lombardy (Italy)
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Impact of anti-androgen therapies on COVID-19 susceptibility: a case-control study in male population from two COVID-19 regional centers of Lombardy (Italy)
Massimo Lazzeri, Stefano Duga, Elena Azzolini, Vittorio Fasulo, Nicolò Buffi, Alberto Saita, The Humanitas COVID-19 Task Force, The Humanitas Gavazzeni COVID-19 Task Force, Rodolfo Hurle, Alessandro Nobili, Maurizio Cecconi, Paolo Casale, Rosanna Asselta
medRxiv 2020.04.20.20068056; doi: https://doi.org/10.1101/2020.04.20.20068056
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Impact of anti-androgen therapies on COVID-19 susceptibility: a case-control study in male population from two COVID-19 regional centers of Lombardy (Italy)
Massimo Lazzeri, Stefano Duga, Elena Azzolini, Vittorio Fasulo, Nicolò Buffi, Alberto Saita, The Humanitas COVID-19 Task Force, The Humanitas Gavazzeni COVID-19 Task Force, Rodolfo Hurle, Alessandro Nobili, Maurizio Cecconi, Paolo Casale, Rosanna Asselta
medRxiv 2020.04.20.20068056; doi: https://doi.org/10.1101/2020.04.20.20068056

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (162)
  • Allergy and Immunology (416)
  • Anesthesia (91)
  • Cardiovascular Medicine (863)
  • Dentistry and Oral Medicine (159)
  • Dermatology (98)
  • Emergency Medicine (251)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (394)
  • Epidemiology (8571)
  • Forensic Medicine (4)
  • Gastroenterology (388)
  • Genetic and Genomic Medicine (1759)
  • Geriatric Medicine (167)
  • Health Economics (373)
  • Health Informatics (1249)
  • Health Policy (622)
  • Health Systems and Quality Improvement (468)
  • Hematology (196)
  • HIV/AIDS (378)
  • Infectious Diseases (except HIV/AIDS) (10318)
  • Intensive Care and Critical Care Medicine (553)
  • Medical Education (192)
  • Medical Ethics (51)
  • Nephrology (213)
  • Neurology (1682)
  • Nursing (97)
  • Nutrition (252)
  • Obstetrics and Gynecology (328)
  • Occupational and Environmental Health (451)
  • Oncology (930)
  • Ophthalmology (264)
  • Orthopedics (102)
  • Otolaryngology (172)
  • Pain Medicine (114)
  • Palliative Medicine (40)
  • Pathology (253)
  • Pediatrics (538)
  • Pharmacology and Therapeutics (254)
  • Primary Care Research (209)
  • Psychiatry and Clinical Psychology (1775)
  • Public and Global Health (3853)
  • Radiology and Imaging (626)
  • Rehabilitation Medicine and Physical Therapy (320)
  • Respiratory Medicine (521)
  • Rheumatology (208)
  • Sexual and Reproductive Health (168)
  • Sports Medicine (158)
  • Surgery (191)
  • Toxicology (36)
  • Transplantation (101)
  • Urology (76)